The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released the agenda for its inaugural 2019 Cell & Gene Meeting on the Mediterranean. This year’s event will be held April 23-25 in Barcelona, Spain.
The event, modeled after ARM’s highly successful Cell & Gene Meeting on the Mesa, is expected to attract more than 250 attendees, including senior executives from leading cell therapy, gene therapy, and tissue engineering companies worldwide, large pharma and biotech representatives, institutional investors, academic research institutions, patient foundations, disease philanthropies, and members of the life science media community.
Featured topics include:
Commercial Strategies from Pathfinders in the Industry
Guido Rasi, Director General, European Medicines Agency (EMA)
The Pricing and Reimbursement Landscape: Opportunities and Challenges
Manufacturing and the CDMO Perspective
Recent Developments and Predictions for the Future of Advanced Therapies
European Clinical Trials in a Global Context
Regulating ATMPs in a Post-Brexit World
Throughout the two-day event, participants can also attend presentations by more than 50 publicly traded and emerging private companies, highlighting clinical and commercial progress in cell therapy, gene and gene-modified cell therapy, tissue engineering, biomaterials and more. In addition to their presentations, representatives from these organizations will also be available for one-on-one partnering opportunities throughout the conference.
The slate of 2019 presenting companies includes: Adaptimmune; Adverum Biotechnologies; AGTC; Andalusian Initiative for Advanced Therapies; Aspect Biosystems; Audentes Therapeutics; Avectas; Axovant Gene Therapies; Biostage; BioTime; bluebird bio; BlueRock Therapeutics; B-MoGen Biotechnologies; Bone Therapeutics; Caribou Biosciences; Cellerant Therapeutics; Chimeric Therapeutics; Cryoport; Cynata Therapeutics; DiscGenics; FUJIFILM Cellular Dynamics; Genethon; Healios; Invitrx Therapeutics; Iovance Biotherapeutics; Kiadis Pharma; LogicBio Therapeutics; Longeveron; Lonza Pharma & Biotech; MaxCyte; MeiraGTx; MolMed; NAVAN Technologies; Orchard Therapeutics; Organovo; Oxford BioMedica; PDC*line Pharma; PolarityTE; Precision BioSciences; Promethera Biosciences; REGENXBIO; ReNeuron; Rexgenero; Sangamo Therapeutics; Seraxis; Sigilon Therapeutics; Spark Therapeutics; Terumo BCT; TikoMed; Tmunity Therapeutics; uniQure; VERIGRAFT; Vivet Therapeutics; and Zelluna Immunotherapy.
For full details on the agenda and further information about the event, please visit www.meetingonthemed.com.
For members of the media interested in attending, please contact Lyndsey Scull at email@example.com.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
# # #